Guangji Pharmaceutical released its 2026 interim report. First-half operating revenue was 312 million yuan, up 9.7 percent year on year. Net loss attributable to the parent was 57.95 million yuan, narrowing from a loss of 75.52 million yuan in the same period last year. Net loss attributable to the parent after deducting non-recurring items was 65.59 million yuan, down from a loss of 78.41 million yuan a year earlier. Net operating cash flow was 43.73 million yuan, up 73.1 percent year on year. Earnings per share were negative 0.1684 yuan. In the second quarter, operating revenue was 149 million yuan, up 9.6 percent year on year. Net loss attributable to the parent was 26.3 million yuan, narrowing from a loss of 39.25 million yuan in the same period last year. Net loss attributable to the parent after deducting non-recurring items was 32.9 million yuan, down from a loss of 41.16 million yuan a year earlier. As of the end of the second quarter, total assets were 2.178 billion yuan, down 5.8 percent from the end of the previous year. Net assets attributable to the parent were 598 million yuan, down 8.6 percent from the end of the previous year. The company's main business is the research, development, production and sale of vitamin raw material products. Its subsidiary Jikang focuses on pharmaceutical preparations and is gradually improving profitability.
Hubei Guangji Pharmaceutical Co LtdFirst-half net loss narrowed to 57.95 million yuan from 75.52 million yuan a year earlier, with revenue up 9.7% and operating cash flow up 73.1%.
Subsidiary Jikang, focused on pharmaceutical preparations, is gradually improving profitability per the interim report.
